Image de couverture de livre

Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Benjamin F. Hartley, Thomas Drury, Brian Di Pace, Helen Zhou, Tai‐Tsang Chen, Inna Perevozskaya
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Statistics in Medicine
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Longitudinal Extension of the Win Odds for Ordinal Repeated Measurements
par: Yongxi Long, et autres
Publié: (2026)

Extending the Median Odds Ratio ( MOR ), the Interval Odds Ratio ( IOR ), and the Proportion of Opposed Odds Ratios ( POOR ) for Use With 3‐Level Multilevel Logistic Regression Models
par: Peter C. Austin, et autres
Publié: (2026)

Cumulative Logit Ordinal Regression With Proportional Odds Under Nonignorable Missing Responses—Application to Phase III Trial
par: Arnab Kumar Maity, et autres
Publié: (2025)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
par: Xinran Huang, et autres
Publié: (2024)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
par: Andrew Hall, et autres
Publié: (2026)

Sample Size and Power Calculations With Win Measures Based on Hierarchical Endpoints
par: Huiman Barnhart, et autres
Publié: (2025)

A Note on the Sample Size Formula for a Win Ratio Endpoint
par: Se Yoon Lee
Publié: (2025)

RMST for Interval‐Censored Data in Oncology Clinical Trials
par: Xiyuan Gao, et autres
Publié: (2025)

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility‐Based Rule
par: Juhee Lee, et autres
Publié: (2024)

Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials
par: Maria Vittoria Chiaruttini, et autres
Publié: (2026)

DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation
par: Meizi Liu, et autres
Publié: (2025)

Semiparametric Inference for a Two‐Phase Failure‐Time‐Auxiliary‐Dependent Sampling Design
par: Xu Cao, et autres
Publié: (2025)

Improved Pharmacovigilance Signal Detection Using Bayesian Generalized Linear Mixed Models
par: Paloma Hauser, et autres
Publié: (2025)

A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin
par: Guangyong Zou, et autres
Publié: (2024)

Multilevel Regression and Poststratification Using Margins of Poststratifiers: Improving Inference for HIV Health Outcomes During the COVID‐19 Pandemic
par: Amy J. Pitts, et autres
Publié: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
par: Cheng‐Han Yang, et autres
Publié: (2026)

What Makes an Estimand Useful? Guidance on the Choice of Intercurrent Event Strategies
par: Brennan C. Kahan, et autres
Publié: (2026)

Some Ways to Make Regression Modeling More Helpful Than Misleading
par: Sander Greenland
Publié: (2025)

Accounting for Patient Characteristics in a Model‐Based Kappa of Agreement Between Two Experts' Ordinal Ratings
par: Kerrie P. Nelson, et autres
Publié: (2025)

Specification of Estimands for Complex Disease Processes Using Multistate Models and Utility Functions
par: Alexandra Bühler, et autres
Publié: (2025)

Robust inference for causal mediation analysis of recurrent event data
par: Yan‐Lin Chen, et autres
Publié: (2024)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
par: Alessandra Serra, et autres
Publié: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
par: Gi‐Ming Wang, et autres
Publié: (2026)

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
par: Rebecca B. Silva, et autres
Publié: (2024)

Multiple Imputation of Missing Covariates When Using the Fine–Gray Model
par: Edouard F. Bonneville, et autres
Publié: (2025)

Improved Centile Estimation by Transformation And/Or Adaptive Smoothing of the Explanatory Variable
par: R. A. Rigby, et autres
Publié: (2026)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
par: Moka Komaki, et autres
Publié: (2026)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
par: Chloe E. Falke, et autres
Publié: (2025)

Estimating generalized propensity scores with survey and attrition weighted data
par: Daniel F. McCaffrey, et autres
Publié: (2024)

Commentary: Regression Models—Efforts Are Required to Improve Statistical Practice and Teaching
par: Willi Sauerbrei, et autres
Publié: (2025)

Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design
par: Yunfei Wang
Publié: (2024)

A class of computational methods to reduce selection bias when designing Phase 3 clinical trials
par: Tianyu Zhan
Publié: (2024)

Combining Biomarkers to Improve Diagnostic Accuracy in Detecting Diseases With Group‐Tested Data
par: Jin Yang, et autres
Publié: (2024)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
par: Hyejung Jung, et autres
Publié: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
par: Yichen Yan, et autres
Publié: (2025)

Improve the Precision of Area Under the Curve Estimation for Recurrent Events Through Covariate Adjustment
par: Jiren Sun, et autres
Publié: (2025)

Modern Causal Inference Approaches to Improve Power for Subgroup Analysis in Randomized Controlled Trials
par: Antonio D'Alessandro, et autres
Publié: (2026)

Bayesian Spatial Relative Survival Model to Estimate the Loss in Life Expectancy and Crude Probability of Death for Cancer Patients
par: Yuliya Leontyeva, et autres
Publié: (2025)

Adding experimental treatment arms to multi‐arm multi‐stage platform trials in progress
par: Thomas Burnett, et autres
Publié: (2024)

Adaptive Seamless Phase II / III Randomization Test Considering Treatment Group Selection Based on Short–Term Binary Outcomes
par: Funato Sato, et autres
Publié: (2026)